Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years

NCT00808028 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00808028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00808028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
March 31, 2014
Enrollment
538 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

meningitis, meningococcal